skip to main content

How gut bacteria evade the immune system

New insight into how harmless gut bacteria avoid triggering inflammation

06.01.2023 Press Release

Researchers from the Max Planck Institute for Biology Tübingen address the long-standing question of how benign gut microbes evade the immune system. In doing so, they also reshape our understanding of how immune receptors interact with the bacterial motility protein flagellin. The scientists identified a new type of flagellin in the human gut, termed ‘silent flagellin’, that binds to the immune receptor Toll-like receptor 5 without inducing a pro-inflammatory response. The findings provide a mechanism for the immune system to tolerate beneficial microbes while remaining responsive to pathogens. Their results now appear in the journal Science Immunology.

The human gut is the habitat of benign, beneficial, and sometimes harmful bacteria. In order to fight off these last-mentioned pathogens, the immune system first recognizes the presence of microbial products via various receptors. One of these is Toll-like receptor 5 (TLR5): it binds flagellin, the protein that makes up the bacterial flagellum, which bacteria use to swim. Once bound to flagellin, TLR5 induces a pro-inflammatory immune response. However, pathogens are not the only gut inhabitants producing flagellin; harmless and beneficial bacteria make it as well. This raises the question of how these beneficial bacteria evade the immune response. While some bacteria avoid TLR5 by producing flagellins that no longer bind the receptor, previous research showed that so-called commensal bacteria, which are harmless to their human hosts, produce flagellins with intact binding sites.

An international team led by researchers from the Max Planck Institute for Biology Tübingen now has an explanation. By screening 116 different flagellins for both TLR5 activation and binding, the researchers found that roughly half were unlike previously described flagellins. These flagellins showed strong binding to TLR5, similar to flagellins from pathogens, but failed to trigger an inflammatory response. Therefore, the scientists termed this new flagellin variant ‘silent flagellins’.  Previously, flagellin binding to TLR5 was thought to be sufficient to activate the inflammatory response. The discovery that commensals produce flagellins that bind TLR5 without initiating an immune response challenges the prior understanding of how TLR5 is turned on.

“We now know that bacterial flagellin can interact with TLR5 at least three in different ways: bind and induce an immune response, bind and not induce an immune response, and evade by not binding,” explains Ruth Ley, senior author of the study, director of the Department of Microbiome Science at the Max Planck Institute for Biology Tübingen and deputy spokesperson at the Cluster of Excellence CMFI. “It is remarkable how tunable the response of the TLR5 receptor is,” she adds.

Subsequent metagenomic analyses showed that silent flagellins are very common in the human gut and therefore represent “a substantial, previously unappreciated, yet physiologically relevant, population of TLR5 binding proteins,” says Sara Clasen, first author of the study. TLR5 is implicated in many gut-related diseases but also plays a role in other disorders such as cancer and neuropathy. The findings provide deeper insights into the mechanism of TLR5 activation and could therefore help better understand TLR5-related diseases.

The study was conducted by researchers from the Max Planck Institute for Biology and the Friedrich Miescher Laboratory in Tübingen, Germany, the Gregor Mendel Institute in Vienna, Austria, the Center for Inflammation, Immunity and Infection at Georgia State University in Atlanta, USA, and the Cluster of Excellence CMFI at the University of Tübingen.
 

(Source: Press Release Max Planck Institute for Biology, January 6, 2023)
 

Original publication:

Clasen SJ, Bell MEW, Borbón A, Lee D, Henseler ZM, De La Cuesta-Zuluaga J, Parys K, Zou J, Wang Y, Altmannova V, Youngblut ND, Weir JR, Gewirtz AT, Belkhadir Y, Ley RE. Silent recognition of flagellins from human gut commensal bacteria by Toll-like receptor 5. Sci. Immunol. 8(79). (2023) doi: 10.1126/sciimmunol.abq7001.

Scientific Contact

Prof. Ruth E. Ley, Ph.D.
Max Planck Institute for Biology Tübingen
Director, Department of Microbiome Science 
Max-Planck-Ring 5
72076 Tübingen, Germany
E-Mail: rley@tuebingen.mpg.de
Phone.: +49 7071 601 450
Website: https://leylab.com/

Press Contact

Leon Kokkoliadis
Public Relations Management

Tel: +49 7071 29-74707
E-Mail: leon.kokkoliadis@uni-tuebingen.de

 

Related Articles

Ruth Ley receives Advanced Grant from the European Research Council
11.04.2024 Ruth Ley receives Advanced Grant from the European Research Council Press Release
Podcast "Bakterien kontrollieren: Gute Bakterien nutzen, böse bekämpfen"
01.04.2024 Podcast "Bakterien kontrollieren: Gute Bakterien nutzen, böse bekämpfen" In the Media

Exzellent erklärt

Decoding new gene functions in the human gut microbiome
26.03.2024 Decoding new gene functions in the human gut microbiome CMFI News
DFG visits CMFI
20.03.2024 DFG visits CMFI CMFI News
Volkswagen Foundation funds project to convert waste into new biomaterials
14.02.2024 Volkswagen Foundation funds project to convert waste into new biomaterials CMFI News
Exploring hidden members in microbial communities
05.02.2024 Exploring hidden members in microbial communities CMFI News
Antibiotics highjack bacterial immunity
19.01.2024 Antibiotics highjack bacterial immunity Press Release
Novel antibiotic substance from the human nose
18.12.2023 Novel antibiotic substance from the human nose Press Release
Unraveling the Impact of Xenobiotics on Gut Microbiota: A High-Throughput Approach under Anaerobic Conditions
13.12.2023 Unraveling the Impact of Xenobiotics on Gut Microbiota: A High-Throughput Approach under Anaerobic Conditions In the Media
"Mikrobiom – Schlüssel zur Gesundheit?"
08.12.2023 "Mikrobiom – Schlüssel zur Gesundheit?" In the Media

Planet Wissen

The Frankenstein molecule: resurrecting an ancient antibiotic to create antibiotics of the future
30.11.2023 The Frankenstein molecule: resurrecting an ancient antibiotic to create antibiotics of the future In the Media

Nature - Behind the paper

Taking antibiotics back in time
30.11.2023 Taking antibiotics back in time Press Release